Stock Screener App

무료 - Play StoreApp Store

설치하다 설치하다

NVS

$164.063.01%4.795

Novartis Ag Adr (NVS)

Date: O: H: L: C: Vol:

Novartis Ag Adr 주식(NVS)의 최신 뉴스

Novartis: 3 Key Takeaways for Long-Term Investors - The Motley Fool

3 Stocks to Watch Following Guidance Upgrades - Zacks Investment Research

BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsight - GlobeNewswire Inc.

Novartis AG : Downgraded from Neutral to Sell by Deutsche Bank - marketscreener.com

Weekly Recap: Q3 $2.2B trial write‑downs and $4.7B share buybacks - TradingView

Novartis AG (NOT.HM) Seasonal returns chart - Yahoo Finance Australia

Novartis AG (NOVN.SW) Seasonal returns chart - Yahoo Finance UK

Novartis AG (NVS) Stock Forecast & Analyst Ratings - Moomoo

Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach (NVS) - Seeking Alpha

NOVN.S News | NOVARTIS AG-REG (SWX:NOVN) - ChartMill

Novartis AG (NVSEF) Seasonal returns chart - Yahoo Finance UK

Novartis AG (NVS.TO) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Novartis AG (NVS) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Novartis AG downgraded by Deutsche Bank - Quantisnow

All You Need to Know About Novartis (NVS) Rating Upgrade to Buy - Zacks Investment Research

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term - Zacks Investment Research

Novartis AG (NOVN.SW) Seasonal returns chart - Yahoo Finance Singapore

Novartis AG (NVS) Seasonal returns chart - Yahoo Finance UK

Novartis AG (NVS) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 79/100 - GuruFocus

China Upends Global Drug Development With Cheap and Rapid Human Trials - Bloomberg.com

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised - Zacks Investment Research

Should You Buy Royalty Pharma Stock Before Nov. 4? - The Motley Fool

Novartis AG (NVS) Stock Forecasts - Yahoo! Finance Canada

Novartis AG : Bernstein reiterates its Neutral rating - www.marketscreener.com

Novartis AG : JP Morgan reiterates its Buy rating - marketscreener.com

Novartis AG Stock 12‑Month Price Target Raised to $158.2, Implies 1% Upside - TradingView

Novartis AG (NVS) Stock Forecasts - Yahoo Finance

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.

How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research

The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie - Zacks Investment Research

Novartis AG (NVS) Stock Forecasts - Yahoo Finance

What Novartis (NVS) Said on Its Q3 Earnings Call - Yahoo Finance

Novartis AG (NVS) (Q3 2026) Earnings Call Highlights: Raised Gui - GuruFocus

Novartis AG (NVS) (Q3 2026) Earnings Call Highlights: Raised Guidance and Priority Brand ... - Yahoo Finance

Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9B Avidity Hit - Novartis (NYSE:NVS) - Benzinga

4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential - Zacks Investment Research

NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss - Zacks Investment Research

Novartis takes $1.9bn writedown on key drug after blockbuster Avidity acquisition - Financial Times

NOVARTIS AG N (NOTA.DU) Q3 FY2026 earnings call transcript - Yahoo Finance

The Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREP - Yahoo Finance

Novartis Raises Outlook on Growth of New Medicines - Bloomberg.com

Novartis lifts profit outlook as new medicines counter generic erosion (NVS:NYSE) - Seeking Alpha

Novartis reports Q3 core EPS $2.46 vs. $2.25 last year - TipRanks

Novartis AG reports results for the quarter ended September 30 - Earnings Summary - TradingView

Novartis Q3 Core Earnings, Net Sales Increase; 2026 Net Sales Growth Outlook Maintained - Yahoo Finance

Novartis: Q3 Earnings Snapshot - Yahoo Finance

Top Analyst Reports for Intel, Novartis & Itau Unibanco - Zacks Investment Research

Earnings To Watch: Novartis AG (XSWX:NOVN) Q3 2026 -- GF Value Sees 8% Downside - Yahoo Finance

Novartis AG : UBS sticks Neutral - marketscreener.com

Novartis MS Pill Trials Trigger Analyst Skepticism on Peak Sales - Bloomberg.com

NVS와(과) 유사한 종목

AZN$188.872.71%

AMGN$473.542.66%

MRK$148.272.49%

GILD$172.843.21%